TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer
21 Outubro 2020 - 5:45AM
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty
pharmaceutical company developing novel nanomedicines to target
areas of unmet medical need, today announced the appointment of
Thomas H. Bliss, Jr., MBA, as the Company’s Chief Business Officer
following the retirement of Wenji Chen, PhD, MBA, from her position
as Vice President of Corporate Development. With decades of
experience accrued from both investment banking and biotech
sectors, Mr. Bliss will take the lead in the Company’s global
corporate and business development efforts, with a key focus on the
Unites States.
“On behalf of TLC, I would like to thank Dr.
Chen for her involvement in the securement of several
collaborations which have aided in the Company’s development
blueprint, and we wish her a very happy and fulfilled retired
life,” said George Yeh, President of TLC. “With the advancement of
our leading programs such as TLC599 into the commercial phase, now
is an opportune time to welcome the return of Mr. Bliss to TLC. We
look forward to successful commercialization and licensing of TLC’s
programs across the globe under Mr. Bliss’s leadership, as well as
to creating benefit and bringing value for all of TLC’s
stakeholders.”
"I am delighted to be returning to TLC, having
been the Company's first Independent Director in the run up to
TLC’s initial public offering (IPO),” said Mr. Bliss. “As a
long-time watcher of TLC, I have observed improvements on all
fronts and am impressed by the ripening pipeline and the efficiency
of the development process of bringing life-changing medicines to
patients. I look forward to working closely with my TLC colleagues
and our external partners to bring these important medicines to
markets across the globe."
Mr. Bliss joins TLC following interim roles in
cellular therapy, drug delivery and combination therapy where he
led efforts to confirm research outcomes and partner the various
technologies. Earlier in his career, he ran business-development
functions at Amgen and Baxter. While at Amgen, Mr. Bliss created
International Licensing, ran M&A and built an entire department
within Research called China/India Research Activities with over
200 contributors and a budget of over $35 million. While at Baxter,
Mr. Bliss completed antibody licenses with Cambridge Antibody
Technologies (later acquired by AstraZeneca) and Dyax (later
acquired by Shire/Takeda) and accelerated the conversion of the
plasma-derived portfolio recombinant alternatives. Mr. Bliss gained
experience in licensing and business development at Johnson &
Johnson after receiving his MBA from Wharton School of the
University of Pennsylvania and his BA from Dartmouth College.
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a
clinical-stage, specialty pharmaceutical company dedicated to the
research and development of novel nanomedicines that maximize the
potential of its proprietary lipid-assembled drug delivery platform
(LipAD™), including BioSeizer® sustained release technology and
NanoX™ active drug loading technology, which are versatile in the
choice of active pharmaceutical ingredients and scalable in
manufacturing. TLC has a diverse, wholly owned portfolio of
therapeutics targeting areas of unmet medical need in pain
management, ophthalmology, oncology and infectious diseases. TLC is
consistently ranked top 5% among all listed companies in Taiwan’s
Corporate Governance Evaluations.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not
guarantees of future performance and involve a number of risks,
assumptions, uncertainties and factors, including risks that the
outcome of any clinical trial is inherently uncertain and product
candidates may prove to be unsafe or ineffective, or may not
achieve commercial approval. Other risks are described in the Risk
Factors section of TLC’s annual report on Form 20-F for the year
ended December 31, 2019 filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on TLC’s
expectations and assumptions as of the date of this press release.
Actual results may differ materially from these forward-looking
statements. Except as required by law, TLC expressly disclaims any
responsibility to update any forward-looking statement contained
herein, whether as a result of new information, future events or
otherwise.
Contact
Dawn Chi
Corporate Communications
dawn@tlcbio.com
Taiwan Liposome (NASDAQ:TLC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Taiwan Liposome (NASDAQ:TLC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024